CD274 and neoplasm: Although PD-L1 that has been completely assessed by immunohistochemistry (IHC) in tumor cells has been approved by the U.S. Food and Drug Administration (FDA) as the only predictive biomarker for selecting patients that undergo ICI, evaluation of outcomes of treatment in NSCLC [7] revealed PD-L1 was not a perfect biomarker.